{"schema_version":"secwatch.filing_event.v1","accession":"0001847903-25-000049","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2025-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.271910+00:00","generated_at":"2026-05-24T06:52:48.488562+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Centessa Q4 net loss widens to $111.3M; cash $482M; OX2R pipeline on track for 2025 data","bullets":["Net loss $111.3M in Q4 2024 vs $36.8M Q4 2023, full-year loss $235.8M.","R&D expenses $60.9M Q4 2024 included $31.5M one-time charge from SerpinPC discontinuation.","Cash, equivalents and short-term investments $482.2M as of Dec 31, 2024; expected to fund into mid-2027.","ORX750 Phase 2a CRYSTAL-1 data in NT1, NT2, and IH expected in 2025; Phase 1 data showed restored wakefulness.","ORX142 and ORX489 advancing in IND-enabling studies with clinical data expected in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001847903-25-000049","json":"https://secwatch.observer/filing/0001847903-25-000049.json","markdown":"https://secwatch.observer/filing/0001847903-25-000049.md","text":"https://secwatch.observer/filing/0001847903-25-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000184790325000049/0001847903-25-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000184790325000049/cnta-20250324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T06:52:48.488562+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}